Primary cutaneous anaplastic large cell lymphoma
MONDO:0017598Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a rare T-cell non-Hodgkin lymphoma that affects the skin and generally shows no extracutaneous involvement at presentation. It belongs to the spectrum of primary cutaneous CD30+ lymphoproliferative disorders along with lymphomatoid papulosis with which it shares overlapping clinical and histopathologic features.
Also known as: ALCL, cutaneous, C-ALCL, anaplastic large-cell lymphoma, primary cutaneous type, primary C-ALCL, primary anaplastic large cell lymphoma of skin, primary anaplastic large cell lymphoma of the skin, primary cutaneous CD30 Positive anaplastic large cell lymphoma, primary cutaneous CD30+ ALCL
3154 clinical trials for this condition and its sub-types, 11 tagged with Primary cutaneous anaplastic large cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a drug duo outsmart resistant T-Cell lymphoma?
Disease control CompletedThis phase II trial is testing whether combining brentuximab vedotin, a targeted antibody-drug conjugate, with lenalidomide, a chemotherapy drug, can shrink tumors in people with T-cell lymphoma that has relapsed or not responded to earlier treatment. The study enrolls adults wit…
Phase 2 • Sponsor: John Reneau • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for rare lymphoma: targeted drug shows promise in small trial
Disease control CompletedThis completed Phase 4 trial tested the drug brentuximab vedotin in 10 Chinese adults with a rare type of skin lymphoma called CD30-positive cutaneous T-cell lymphoma. The goal was to see if the drug could shrink or eliminate cancer for at least 4 months and to check for long-ter…
Phase 4 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 26, 2026 18:32 UTC